InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,829.44
(
0.96%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
-0.64%
)
Bitcoin
56,590.93
(
-0.68%
)
Post# of 704017
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DocLee

Send PM Follow Ignore
Followers 25
Posts 560
Boards Moderated 0
Alias Born 06/11/2011

DocLee

Re: SkyLimit2022 post# 544294

Tuesday, 12/06/2022 7:53:55 AM

Tuesday, December 06, 2022 7:53:55 AM

Post# of 704017
Can somebody enlighten me about the difference between "Neoadj PD1 mAB" and "PD-1 mAB" being used in the phase 1 study reported in the message by Skylimit to which this is a reply. I have looked at the trial design in clinicaltrials.gov and cannot determine the answer from that.
PD-1 is clearly Pembrolizumab and ATL-DC is the UCLA produced version of DCVax-L but the only conclusion I can draw is that "Neoadj PD1 mAB" means "placebo for PD1 mAB" . Is this correct and is "neoadj" an accepted code for "placebo"?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News
InvestorsHub NewsWire

Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM

Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM

EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM

BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM

NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM

Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM

Start posting your company's news
Only $200 per official company press release!